Manufacturing the next generation of pharmaceuticals – Our expertise in successful project proposals helped secure €6.3 million in funding for a pilot plant to produce polymer-based nano-pharmaceuticals in the NanoPilot project.
NanoPilot will set-up a flexible and adaptable pilot plant operating under GMP for the production of small batches of polymer-based nanopharmaceuticals, which exhibit significant potential in the field of drug-delivery particularly for the design of second-generation nanopharmaceuticals.
How we reached the goals?
The goal is to establish a pilot plant enabling high-quality custom manufacturing of early-stage clinical batches of sterile nano-pharmaceuticals.
Spinverse assisted Cidetec, an RK4 Research Alliance technology center in Spain, in its project proposal and business plan for NanoPilot and participates in the project as a partner during its active phase
NanoPilot received funding from the European Union Framework Programme for Research and Innovation Horizon 2020. The objective of this four-year long project is to set-up a pilot plant operating under Good Manufacturing Practice (GMP) for the production of polymer-based nanopharmaceutical, accelerating the development of nanomedicine, currently in its infancy within the pharmaceutical sector.
Photo credit: Ousa Chea